New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon (Q36089497)

12 August 2017

New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon (English)

1 reference

12 August 2017

anti-retroviral agent

0 references

Cameroon

0 references

author

Dominique Costagliola

series ordinal

7

object named as

Dominique Costagliola

0 references

Sinata Koulla-Shiro

series ordinal

4

object named as

Sinata Koulla-Shiro

1 reference

12 August 2017

Eric Delaporte

3

0 references

Xavier Anglaret

series ordinal

2

object named as

Xavier Anglaret

1 reference

12 August 2017

5

Delphine Gabillard

1 reference

12 August 2017

1

Jacques D A Ndawinz

1 reference

12 August 2017

6

Albert Minga

1 reference

12 August 2017

8

Virginie Supervie

1 reference

PMC publication ID

4581657

12 August 2017

language of work or name

English

0 references

publication date

1 June 2015

1 reference

Bulletin of the World Health Organization

12 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

12 August 2017

93

1 reference

12 August 2017

8

1 reference

12 August 2017

521-528

1 reference

Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

The future role of CD4 cell count for monitoring antiretroviral therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Update on HIV-1 diversity in Africa: a decade in review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Prevention of HIV-1 infection with early antiretroviral therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Early versus standard antiretroviral therapy for HIV-infected adults in Haiti

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Does the covariance structure matter in longitudinal modelling for the prediction of future CD4 counts?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

Random-effects models for longitudinal data

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

How should access to antiretroviral treatment be measured?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a f

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581657

23 September 2018

Identifiers

DOI

10.2471/BLT.14.147892

1 reference

12 August 2017

1 reference

PMC publication ID

4581657

12 August 2017

PubMed publication ID

26478609

1 reference

PMC publication ID

4581657